Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology

Betsy Goodfellow | August 10, 2023 | News story | Business Services Glympse Bio, Oncology, Sunbird Bio, merger, oncology 

Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to accelerate the development of both companies’ protein-based diagnostic platforms. The merged company will operate under the Sunbird Bio name, and brings together the two leading companies’ technology, resources and expertise.

The newly merged company will have headquarters in Cambridge, Massachusetts, US, with another facility in Singapore. The company’s pipeline includes diagnostic tests based on the two companies’ technology platforms, APEX and Glympse, both of which have demonstrated potential to provide diagnostic tests that are more cost-effective, sensitive, accessible and reliable. All of this will help to accelerate drug development processes and patient care.

John McDonough, executive chair and CEO of Sunbird Bio, commented: “I am excited about the synergies and opportunities created by the integration of our two innovative companies – particularly the impact our combined diagnostic offerings could have on accelerating clinical research and the availability of new treatments for patients suffering from serious diseases. The APEX and Glympse platforms have the potential to dramatically improve standards of care for many diseases by overcoming the inaccessibility, invasiveness and lack of reliability associated with current diagnostic approaches that limit their usefulness in drug development, disease detection, disease monitoring and personalised treatment selection.”

Alexandra Cantley, partner at Polaris Partners, one of the company’s investors, added: “By joining two companies with unparalleled scientific leadership in protein-based diagnostics, Sunbird Bio is well-positioned to become a global leader in the field, addressing significant research and clinical gaps, and serving multiple, sizable markets. The company’s diagnostic platforms could be highly complementary as technologies that detect, measure and monitor disease, helping to fuel advances in Alzheimer’s disease, other neurological disorders and early-stage cancer, with long-term potential in other therapeutic areas, as well.”

Betsy Goodfellow

Related Content

BioIVT acquires PrecisionMed for neurology and oncology research

BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological …


UK nonprofit National Cancer Research Institute to close

The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years …

XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets

US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone …

Latest content